Dr. Matthias Nees (PhD) has held positions in both industry and academia. He has used and developed a number of organotypic model systems, such as raft cultures and xenograft models, established tumor cell lines from cancer tissues, and developed numerous assays for in vitro testing and screening of both gene functions and small-molecule inhibitors. This led to his role in the biotech industry (VTT Technical Research Centre of Finland, 2005–2015), developing high throughput and high content drug screening for partners in the pharmaceutical industry, and developing standardized and miniaturized 3D models for early-stage drug discovery. Dr. Nees has engaged in multiple academic (also EU) and commercial projects, including public/private partnerships (e.g., IMI), and numerous cooperations with other pharmaceutical companies or custom research organizations (CROs) that provide high-content screening services, assays, and model systems. The 3D models increased in complexity over time, now also addressing the role of the tumor microenvironment (TME, including cancer-associated fibroblasts, endothelial cells, and immune cells) and the extracellular matrix (ECM) in the chemosensitivity of cancer cells to experimental drugs or drug combinations.
Dr. Matthias Nees (PhD) has held positions in both industry and academia. He has used and developed a number of organotypic model systems, such as raft cultures and xenograft models, established tumor cell lines from cancer tissues, and developed numerous assays for in vitro testing and screening of both gene functions and small-molecule inhibitors. This led to his role in the biotech industry (VTT Technical Research Centre of Finland, 2005–2015), developing high throughput and high content drug screening for partners in the pharmaceutical industry, and developing standardized and miniaturized 3D models for early-stage drug discovery. Dr. Nees has engaged in multiple academic (also EU) and commercial projects, including public/private partnerships (e.g., IMI), and numerous cooperations with other pharmaceutical companies or custom research organizations (CROs) that provide high-content screening services, assays, and model systems. The 3D models increased in complexity over time, now also addressing the role of the tumor microenvironment (TME, including cancer-associated fibroblasts, endothelial cells, and immune cells) and the extracellular matrix (ECM) in the chemosensitivity of cancer cells to experimental drugs or drug combinations.